A review examining seven decades of research argues that evidence linking cholesterol directly to cardiovascular disease is far less consistent than prevailing medical guidelines have long suggested.
By yourNEWS Media Newsroom
A new review examining 380 studies is challenging one of the most entrenched ideas in cardiovascular medicine: that elevated cholesterol, particularly LDL cholesterol, is a primary cause of heart disease and that lowering it should remain a central strategy for preventing heart attacks.
The review, conducted by researchers in Spain, assessed major clinical trials, observational studies and cohort research published across roughly seven decades. According to the report, 41% of the evidence reviewed supported the hypothesis that cholesterol is a principal driver of cardiovascular disease, while 42% opposed that conclusion. The remaining studies were classified as neutral.
The authors reported no financial conflicts of interest.
The findings come as cardiovascular disease continues to rank as the leading cause of death in the United States despite decades of cholesterol screening, dietary recommendations and widespread use of cholesterol-lowering medications.
Rather than finding a clear scientific consensus across the literature, the review describes a divided body of evidence and argues that cardiovascular risk may be considerably more complex than a single cholesterol measurement can capture.
The researchers’ conclusions also reopen questions about how cholesterol became such a dominant focus of heart disease prevention in the first place.
Much of the modern dietary framework surrounding cholesterol and saturated fat can be traced to research conducted during the middle of the 20th century, including the Seven Countries Study.
That research compared dietary patterns, saturated fat consumption and rates of cardiovascular disease in selected countries and reported a strong association between higher saturated fat intake and heart disease.
According to the report, however, analysis involving a broader 22-country dataset produced a correlation of 0.62, substantially lower than the 0.87 correlation reported when only selected countries were examined.
The review argues that decisions over which countries and data points were emphasized helped establish a dietary narrative that would influence medical recommendations for decades.
Cholesterol targets became increasingly aggressive as that framework was incorporated into clinical practice.
In 2004, a government panel recommended lowering the optimal LDL cholesterol level to below 100 milligrams per deciliter. The change substantially expanded the number of people who could be considered candidates for cholesterol-lowering therapy.
According to the report, eight of the nine members of that panel had financial relationships with companies manufacturing statin medications.
The review also points to other instances in which researchers, guideline authors and pharmaceutical manufacturers had financial connections.
One controversy occurred in Australia in 2014, when a television documentary questioning prevailing views on cholesterol and statin therapy was removed from broadcast following complaints from the Australian Heart Foundation and three major statin manufacturers, according to the report.
Those historical disputes are significant because recommendations established during that period helped shape cholesterol thresholds and treatment practices that continue to influence cardiovascular care.
The new review also scrutinizes whether major clinical trials consistently produced the outcomes expected under the traditional cholesterol hypothesis.
One of the largest examples cited is the Women’s Health Initiative, which followed 48,835 women for eight years.
The trial examined whether reducing dietary fat would lower cardiovascular risk. According to the report, women following the lower-fat dietary intervention did not experience significant reductions in heart attacks, strokes or deaths.
Another frequently cited study, the Lyon Diet Heart Trial, produced striking cardiovascular improvements despite relatively little change in cholesterol levels.
Participants following a Mediterranean-style eating pattern experienced an approximately 70% reduction in coronary events, according to the report, while cholesterol measurements remained largely unchanged.
That finding raises a different question: whether the cardiovascular benefits associated with certain dietary patterns may operate through mechanisms extending beyond LDL reduction.
Recovered data from other dietary studies have also complicated the traditional framework.
According to analyses cited in the report, replacing saturated fats with certain vegetable oils reduced cholesterol but was associated with increased mortality from all causes, including coronary heart disease.
The review argues that findings of that kind are difficult to reconcile with a model in which reducing cholesterol should predictably produce corresponding reductions in cardiovascular deaths.
Statin studies are another major focus of the analysis, particularly the way treatment benefits are communicated.
Clinical trials frequently describe a drug’s effectiveness through relative risk reduction. While mathematically valid, relative risk can produce a much larger-looking percentage than the absolute difference in outcomes between treated and untreated groups.
For example, if the risk of an event falls from 4% to 3%, the absolute reduction is 1 percentage point, while the relative reduction is 25%.
According to the report, some statin trials that appear to demonstrate substantial benefits when expressed in relative terms translate into absolute risk reductions of approximately 2% to 3%.
The distinction matters because absolute risk determines how many people must receive treatment before one cardiovascular event is prevented.
The report estimates that roughly 50 people may need to take cholesterol-lowering medication over the applicable treatment period for one person to avoid a heart attack.
Other analyses cited in the report have similarly concluded that more than 50 adults may need to receive cholesterol-lowering medication for one high-risk patient to avoid a fatal heart attack.
Another estimate cited states that approximately 100 people would need to take a statin for two and a half years to prevent one episode of heart disease, meaning 99 of those treated would not experience that particular preventive benefit during the period studied.
Those figures do not establish that statins provide no benefit. Rather, the review argues that patients should understand the difference between relative and absolute risk when evaluating the magnitude of a treatment’s effect.
The authors also advocate examining cardiovascular health through a broader metabolic and inflammatory framework instead of relying predominantly on LDL cholesterol.
Diet is one component of that approach.
The report points to Mediterranean-style dietary patterns emphasizing foods such as wild-caught fish, extra virgin olive oil, leafy greens and a variety of colorful vegetables. Such foods contain nutrients and compounds associated with lower levels of inflammation and have performed well in cardiovascular studies.
Replacing refined carbohydrates with minimally processed whole foods may also affect blood sugar regulation, insulin response and inflammatory processes that researchers have increasingly examined in connection with cardiovascular disease.
Under this approach, cholesterol remains one piece of the cardiovascular picture rather than the sole laboratory measurement determining risk.
The report recommends considering inflammatory and metabolic markers alongside conventional cholesterol testing.
High-sensitivity C-reactive protein, commonly called hs-CRP, can provide information about systemic inflammation. Fasting insulin can help identify disturbances in metabolic regulation, while the triglyceride-to-HDL ratio may offer additional insight into a person’s metabolic condition.
The authors argue that those measurements can reveal cardiovascular risk factors that an isolated LDL cholesterol number may not detect.
Lifestyle factors also figure prominently in the review’s broader model of cardiovascular health.
Poor sleep, chronic psychological stress and physical inactivity can influence metabolic function and inflammatory pathways. Regular physical activity, consistent sleep and stress-management practices may therefore address cardiovascular mechanisms that extend well beyond cholesterol production or absorption.
A daily walk, for example, can affect insulin sensitivity, cardiovascular fitness and metabolic health, while adequate sleep and stress reduction can influence hormonal and inflammatory processes.
The review ultimately questions whether decades of cholesterol-centered guidelines have placed disproportionate emphasis on one biomarker while giving insufficient weight to the broader biological conditions associated with cardiovascular disease.
According to the report, researchers have not consistently demonstrated that elevated cholesterol by itself predicts cardiovascular disease across all populations. Some studies reviewed have even reported associations between higher cholesterol and better outcomes among certain groups.
Those findings do not establish that elevated cholesterol is harmless or that cholesterol-lowering treatment should be abandoned. They instead underscore the disagreement identified across the scientific literature and the difficulty of reducing cardiovascular disease to one risk factor.
The review’s authors contend that cardiovascular prevention should incorporate inflammation, glucose regulation, insulin function, diet, physical activity, sleep and other metabolic factors alongside conventional lipid testing.
Their analysis also raises questions about the process through which treatment guidelines are developed, particularly when researchers or panel members have financial relationships with companies that manufacture therapies affected by those recommendations.
With 41% of the evidence examined supporting the cholesterol hypothesis and 42% opposing it, according to the review’s classification, the authors argue that the scientific record is substantially more contested than four decades of cholesterol-focused public health messaging might imply.
The report consequently calls for renewed scrutiny of both the evidence underlying existing guidelines and the way cardiovascular risk is communicated to patients.
Rather than treating one laboratory value as a definitive measure of heart health, the researchers favor a more comprehensive assessment that considers cholesterol in conjunction with inflammation, metabolic function, blood sugar regulation and the overall health of the individual.
Explainer Infographic
Comments